[ad_1]
Based on the interactive map developed by Johns Hopkins University scientists at the time of writing SARS-CoV-2 coronavirus officially infected more than 82 million people worldwide and killed 1.8 million (in Italy total infections are more than 2 million and deaths almost 74 thousand). The numbers are growing steadily and Second wave it is taking a very high toll, especially in Europe and the United States. Fortunately, the first ones have been approved in recent weeks. Vaccines for COVID-19 in the West, and the hope is that in the course of 2021, thanks to the spread of these medicines, the enemy who has caused an unprecedented health, social and economic catastrophe can be brought down. To do this you will need more preparations, precisely because there is a need to vaccinate a large number of people, impossible to cover relatively quickly with a single manufacturer. It is also for this reason that the imminent approval for emergency use of the vaccine Moderna Inc. me NIAID for himEMA, the European Medicines Agency, is excellent news after the ok to BNT162b2 developed by Pfizer me BioNTech. The extraordinary meeting of the EMA expert committee that will decide the green light is scheduled for Wednesday, January 6, and there should be no “surprises”, considering that the vaccine was already approved on December 18 by the Food and Drug Administration. (FDA) American.
But the availability of a second vaccine against the SARS-CoV-2 coronavirus does not increase our chances of winning the battle just by a matter of numbers; l ‘MRNA-1273, this is the name of the preparation developed by Moderna in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) led by Anthony Fauci, in fact it is also extremely effective me Of course. To underline this there is also the voice of the teacher Roberto Burioni, Professor of Microbiology and Virology at the Vita-Salute San Raffaele University in Milan, who in an enthusiastic Facebook post said that “it was not possible to ask for better”, given that we now have “two safe and monstrously effective vaccines”, sparing no not even a dig into “owls and suspects.” Specifically, the reference is to the results of the study “Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine” published in the authoritative scientific journal The New England Journal of Medicine, the most authorized in the world in the field of medicine.
The study results, which are similar to the FDA approval document, remind us that Moderna-NIAID’s vaccine has a94.1 percent effective against COVID-19 and 100 percent againstsevere infection. Simply put, only 5 out of 100 vaccinated people develop i symptoms of infection when exposed to the SARS-CoV-2 coronavirus, but none of them manifest them in the serious and life-threatening form. The data emerged from the phase 3 clinical trial that involved more than 30,000 volunteers, half treated with a placebo and the other half with two injections of 100 micrograms of mRNA-1273, a messenger RNA-based vaccine for protein S OR Spike coronavirus like Pfizer’s, which once introduced pushes our cells to produce it and immune system recognize it, developing accordingly antibodies to neutralize it. The results in the tolerability of the vaccine, although it has a reactogenicity more “intense” than a regular flu vaccine, as some experts put it in an editorial published in the authoritative scientific journal Science. The reason would be in the lipid polyethylene glycol (PEG) nanoparticles that act as “transport shuttles” for the messenger RNA, although the role of another of the excipients of the drug is not excluded (here the list of the “ingredients” of the preparations by Pfizer and Moderna).
As to side effects real, the most common happen to be injection site pain, fatigue, headache, Muscle pain, joint pain and chills. Rare the serious adverse reactions registered during clinical trials and at the beginning of the vaccination campaign. An American physician from Boston Medical Center allergic to shellfish developed an anaphylactic reaction, but his colleagues treated him immediately and survived the crisis, as did all the other patients who had an exaggerated immune response to COVID vaccines, less than 10 people in the US over 1 million vaccinated, as indicated by the New York Times. Finally, do not forget that Moderna’s vaccine can be stored for a month in fridge between 2 and 8 ° C and the next six months at -20 ° C, while the Pfizer vaccine needs a temperature of -70 ° C, which makes the logistics a bit more complicated (but perfectly manageable with the tools adequate). In short, there are many reasons to be happy with the approval of Moderna’s vaccine. Professor Franco Locatelli, president of the Higher Health Council and member of the technical scientific committee announced that 62 million doses of Moderna and Pfizer will arrive in Italy, and others will arrive in the future from AstraZeneca, Curevac and Johnson & Johnson; Together they will create an unprecedented vaccination campaign that we all hope will get us out of this nightmare as soon as possible.
window._fpcmp.push(function(gdpr)
{
!function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};
if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0';
n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];
s.parentNode.insertBefore(t,s)}(window, document,'script',
'https://connect.facebook.net/en_US/fbevents.js');
fbq('init', '2062554930705272');
fbq('track', 'PageView');
//fbq('track', 'ViewContent');
//send custom checkpoints event
(function () {
var checkPoints = [10, 20, 40, 60, 90, 120, 180, 240, 300].sort(function(a, b) {
return a - b;
}); //seconds
var checkPointIndex = 0;
var f = function(){
var data = {
instant: checkPoints[checkPointIndex]
};
console.log("[FB PIXEL] send custom event ViewContentCheckPoint ", data, " on account " ,"2062554930705272" , " currentTime in seconds ",
new Date().getTime() / 1000);
fbq('trackCustom', 'ViewContentCheckPoint', data);
checkPointIndex++;
if(checkPointIndex < checkPoints.length) {
setTimeout(f, (checkPoints[checkPointIndex] - checkPoints[checkPointIndex-1]) * 1000)
}
};
if(checkPoints.length){
setTimeout(f, checkPoints[checkPointIndex] * 1000)
}
})();
});
[ad_2]